The Cannabis Legal Landscape Today

Erika Lietzan University of Missouri School of Law

November 2018



Controlled Substances Act

- Schedule I: "marihuana" and "tetrahydrocannabinols"
- What is "marihuana"? Defined as all parts of the plant *Cannabis sativa L,* the seeds, extracted resin, and any derivative of these things.
- Does not include mature stalks, fiber from the stalks, oil or cake made from the seeds, or compounds made from the same.





State Laws



From NCSL website



Federal Response

- Medical cannabis: 2009 **Ogden Memo** to U.S. Attorneys. Deprioritize prosecution if individual clearly complying with state law.
- Adult/recreational cannabis: 2013 **Cole Memo** to U.S. Attorneys. Eight priorities for resource allocation.

- Preventing the distribution of marijuana to minors;
- Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels;
- Preventing the diversion of marijuana from states where it is legal under state law in some form to other states;
- Preventing state-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;
 - Preventing violence and the use of firearms in the cultivation and distribution of marijuana;
 - Preventing drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use;
 - Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and
 - Preventing marijuana possession or use on federal property.

Federal Response / Situation Today

• Marijuana in general: 2018 Sessions Memo to U.S. Attorneys.

In deciding which marijuana activities to prosecute under these laws with the Department's finite resources, prosecutors should follow the well-established principles that govern all federal prosecutions. Attorney General Benjamin Civiletti originally set forth these principles in 1980, and they have been refined over time, as reflected in chapter 9-27.000 of the U.S. Attorneys' Manual. These principles require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.

Consolidated Appropriations Act, 2018, H.R. 1625 § 538 None of the funds car

SEC. 538. None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York,

North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.



None of the funds can be used

to **prevent** any of these states

from **implementing** its own laws

that authorize . . . medical marijuana

What About Descheduling?

- The Attorney General could do it or Congress could do it
- AG process involves FDA
- FDA's views on medical and scientific issues is binding
- DEA has declined requests to reschedule cannabis, including requests from state governments





- Each Party shall establish as a criminal offence . . . the cultivation of cannabis plant for the purpose of the production of narcotic drugs . . .
- The use of cannabis for other than medical and scientific purposes must be discontinued as soon as possible but in any case within 25 years from the coming into force of this Convention



Medical Use of the Cannabis Plant

- Medical research: cannabis grown at the University of Mississippi and distributed by the National Institute on Drug Abuse (NIDA)
- Differing concentrations of delta-9-THC and cannabidiol (CBD)
- But lots of criticism from researchers

THE UNIVERSITY OF MISSISSIPPI

Marijuana Research

About	NIDA Contract	Prod

Products Cannabis R&D

Potency Monitoring



Synthetic Cannabinoids



Contains synthetic delta-9-THC, assigned the nonproprietary name dronabinol Contains a cannabinoid similar to delta-9-THC, with the name nabilone.



Naturally Derived Cannabinoid



First approved new drug derived directly from the *cannabis* plant
Not the first new drug with botanical origins
Not a botanical NDA
No abuse potential, according to FDA reviewers, so placed in Schedule V

Clinical Investigations

- Numerous clinical trials published or ongoing
- Looking at pain, neurological conditions, psychiatric conditions
 - Using cannabis from Ole Miss
 - Or at the state level: "bring-your-own"
 - <u>Or</u> outside the United States



110000



Become a Member | Donate

How to Shop for CBD

Thousands of the cannabis products line store shelves, but determining what's safe is up to you

> STRENGTH HEMP EXTRACT

Our highest level of CBD





food purpose?

Dietary Supplements



maybe

SALE!

function claims?

Home / CBD (Hemp) / CBD Gummies (Hemp)

CBD Gummies (Hemp) ***** (1 customer review) \$17.99 \$15.99 Flavor Choose an option



Medix CBD Edible Chews – Citrus Strawberry (150 MG)

\$45.99

Controlled Substances Act

 <u>All</u> parts of the plant *Cannabis* sativa L, the seeds, extracted resin, and any derivative of these things falls in Schedule I.

 (but not mature stalks, fiber from the stalks, oil or cake made from the seeds, or compounds made from the same)

Requirements for Handling FDA-Approved Products Containing CBD

As noted, until now, Epidiolex has been a schedule I controlled substance. By virtue of this order, Epidiolex (and any generic versions of the same formulation that might be approved by the FDA in the future) will be a schedule V controlled substance. Thus, all persons in the distribution chain who handle Epidiolex in the United States (importers, manufacturers, distributors, and practitioners) must comply with the requirements of the CSA and DEA regulations relating to schedule V controlled substances. As

83 Fed. Reg. 48950 (Sept. 28, 2018)



Post Script

- For more of this background information, please read my article with Sean O'Connor, *The Surprising Reach of FDA Regulation of Cannabis, Even after Descheduling,* forthcoming in the AMERICAN UNIVERSITY LAW REVIEW
- Available on SSRN.COM (just search "Lietzan")